motesanib
Motesanib is an experimental drug candidate originally developed by Amgen but later investigated by the Takeda Pharmaceutical Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors. It is used as the phosphate salt motesanib diphosphate. After clinical trials in thyroid cancer, non-small cell lung cancer, gastrointestinal stromal cancer, colorectal cancer, and breast cancer, the drug was not found to show sufficient efficacy for further development, and development was abandoned by Takeda. — Wikipedia
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2005 (NCT00094835)
Timeline
Indications
Mechanism of action
- Bile salt export pumpINHIBITOR
ABCB11 inhibitor
Chemistry & pharmacology
SMILES
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21- Mol. weight
- 373.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL572881 ↗
- WikipediaMotesanib ↗
- ChEMBLCHEMBL2107357 ↗
Also known as
- motesanib
- motesanib
- motesanib
- motesanib
- motesanib diphosphate
- motesanib diphosphate
- motesanib diphosphate
- motesanib diphosphate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01349088 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Amgen, Susan G. Komen Breast Cancer Foundation, Thomas Jefferson University |
| NCT02629848 | Phase 3 | Jul 1, 2012 | Takeda |
| NCT00574951 | Phase 2 | Dec 1, 2007 | Gynecologic Oncology Group, National Cancer Institute (NCI), Temple University |
| NCT00324597 | Phase 1 | Oct 1, 2005 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00094835 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2005 | Amgen |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 2 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2005 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Susan G. Komen Breast Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Takeda | For profit | 1 | 1 | 1 | 2012 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2005 |